In the last years, the concept that any disease-modifying treatment for neurodegenerative disorders should be started before irreversible neuronal damage occurs became widely accepted. As a consequence, it is increasingly important to make the diagnosis as early in the disease process as possible, often in rather young cases. The presence of cerebral amyloid pathology, the marker of Alzheimer’s disease, as determined by positron emission tomography or cerebrospinal fluid abnormalities, is found in healthy people from the fifties on. Cerebral amyloid pathology is associated with APOE genotype and cognitive impairment. It seems a there is long 20- to 30-year interval between the first development of amyloid positivity and the onset of dementia, suggesting a promising time window opportunity for prevention.
The seminar is free, and all are welcome (including members of the public) without needing to book a place.
Alexandre de Mendonça graduated at the Faculty of Medicine, University of Lisbon, in 1982, obtained the title of Specialist in Neurology in 1991, the Ph.D. degree in Medicine (Neurology) at the University of Lisbon in 1995 and accomplished the “Agregação” degree in Medicine (Neurology) at the University of Lisbon in 2001. He is presently Principal Investigator at the Faculty of Medicine, University of Lisbon. His main scientific areas of research are the cognitive decline of ageing and the neurophysiological basis for memory. He participated and coordinated research projects on basic neurosciences as well as clinical trials in dementia and mild cognitive impairment, and is author of more than one hundred full publications in international journals subjected to peer review. Prof. Alexandre de Mendonça is member of the Scientific Committee of Associação de Familiares e Amigos de Doentes de Alzheimer, Scientific Committee of Sociedade Portuguesa de Neurologia, Comissão de Ética para a Investigação Clínica and is the coordinator of the Lisbon centre of the European Alzheimer´s Disease Consortium.